Advertisement

CardioVascular and Interventional Radiology

, Volume 31, Issue 2, pp 269–280 | Cite as

Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients

  • Katerina Malagari
  • Katerina Chatzimichael
  • Efthymia Alexopoulou
  • Alexios Kelekis
  • Brenda Hall
  • Spyridon Dourakis
  • Spyridon Delis
  • Athanasios Gouliamos
  • Dimitrios Kelekis
Clinical Investigation

Abstract

The purpose of this study was to assess the safety and efficacy of doxorubicin-loaded beads (DC Beads) delivered by transarterial embolization for the treatment of unresectable hepatocellular carcinoma (HCC). This open-label, single-center, single-arm study included 62 cirrhotic patients with documented single unresectable HCC. Mean tumor diameter was 5.6 cm (range, 3–9 cm) classified as Okuda stages 1 (n = 53) and 2 (n = 9). Patients received repeat embolizations with doxorubicin-loaded beads every 3 months (maximum of three). The maximum doxorubicin dose was 150 mg per embolization, loaded in DC Beads of 100–300 or 300–500 μm. Regarding efficacy, overall, an objective response according to the European Association for the Study of the Liver criteria was observed in 59.6%, 81.8%, and 70.8% across three treatments. A complete response was observed in 4.8% after the first procedure and 3.6% and 8.3% after the second and third procedures, respectively. At 9 months a complete response was seen in 12.2%, an objective response in 80.7%, progressive disease in 6.8%, and 12.2% showed stable disease. Mean tumor necrosis ranged from 77.4% to 83.9% (range, 28.6%–100%) across three treatments. α-Fetoprotein levels showed a mean decrease of 1123 ng/ml (95% CI = 846–1399; = 3 × 10–11) after the first session and remained stable after the second and third embolizations (42 and 70 ng/ml decrease, respectively). Regarding safety, bilirubin, γ-glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase showed only transient increases during the study period. Severe procedure-related complications were seen in 3.2% (cholecystitis, = 1; liver abscess, = 1). Postembolization syndrome was observed in all patients. We conclude that hemoembolization using doxorubicin-loaded DC Beads is a safe and effective treatment of HCC as demonstrated by the low complication rate, increased tumor response, and sustained reduction of α-fetoprotein levels.

Keywords

Hepatocellular carcinoma Doxorubicin Embolization Drug-eluting beads 

Notes

Acknowledgments

We would like to thank the scientific department of Biocompatibles UK Ltd. (Farnham, Surrey, UK), particularly Eva Gallardo, Samantha Ryan, and Brenda Hall, for their valuable assistance with the statistical analysis and preparation of the manuscript.

References

  1. 1.
    Brown DB, Geschwind JF, Soulen MC, et al. (2006) Society of interventional radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17:217–230PubMedGoogle Scholar
  2. 2.
    Lo CM, Ngan H, Tso WK, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRefGoogle Scholar
  3. 3.
    Llovet JM, Real MI, Montana X, et al. (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRefGoogle Scholar
  5. 5.
    Camma C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–454PubMedCrossRefGoogle Scholar
  6. 6.
    Νakamura H, Hashimoto T, Oi H, et al. (1988) Iodized oil in the portal vein after arterial embolization. Radiology 167:415–417Google Scholar
  7. 7.
    Kawai S, Okamura J, Ogawa M, et al. (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31(Suppl):S1–S6PubMedCrossRefGoogle Scholar
  8. 8.
    Chang JM, Tzeng WS, Pan HB, et al. (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449–2453Google Scholar
  9. 9.
    Raoul JL, Heresbach D, Bretagne JF (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585–590PubMedCrossRefGoogle Scholar
  10. 10.
    Kanematsu T, Furuta T, Tkemada K, et al. (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Ηepatology 10(1):98–102CrossRefGoogle Scholar
  11. 11.
    Sasaki Y, Imaoka S, Kasugai H, et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60:1194–1203PubMedCrossRefGoogle Scholar
  12. 12.
    Lewis AL, Gonzales MV, Lloyd AW, et al. (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342PubMedGoogle Scholar
  13. 13.
    Hong K, Khwaja A, Liapi E, et al. (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567PubMedCrossRefGoogle Scholar
  14. 14.
    Varela M, Real ML, Burrel M, et al. (2007) Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–478PubMedCrossRefGoogle Scholar
  15. 15.
    Βruix J, Shermamn M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefGoogle Scholar
  16. 16.
    Τakayasu K, Maeda T, Iwata R (2002) Sensitivity of superselective angiography for small hepatocellular carcinoma compared with proximal arteriography and computed tomography during superselective arteriography. Jpn J Clin Oncol 32:191–195CrossRefGoogle Scholar
  17. 17.
    Reidy DL, Schwartz JD (2004) Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials. I. Hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 15:427–437PubMedCrossRefGoogle Scholar
  18. 18.
    Pelletier G, Roche A, Ink O, et al. (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184PubMedCrossRefGoogle Scholar
  19. 19.
    Lin DY, Liaw YF, Lee TY, et al. (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology 94:453–456PubMedGoogle Scholar
  20. 20.
    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261CrossRefGoogle Scholar
  21. 21.
    Bruix J, Llovet JM, Castells A, et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583PubMedCrossRefGoogle Scholar
  22. 22.
    Pelletier G, Ducreux M, Gay F, et al. (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29:129–134PubMedCrossRefGoogle Scholar
  23. 23.
    Kasugai H, Kojima J, Tatsuta M, et al. (1989) Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 97:965–971PubMedGoogle Scholar
  24. 24.
    Μatsui O, Kadoya M, Yoshikawa J, et al. (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83Google Scholar
  25. 25.
    Lewis AL, Taylor RR, Hall B, et al. (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation. J Vasc Interv Radiol 17:1335–1343PubMedCrossRefGoogle Scholar
  26. 26.
    Ball DS, Heckman R, Olenick SW, et al. (2003) In vitro stability of tris-acryl gelatin microspherew in a multipharmaceutical chemoembolization solution. J Vasc Interv Radiol 14:83–88PubMedGoogle Scholar
  27. 27.
    Johnson PJ, Kalayci C, Dobbs N, et al. (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120–127PubMedCrossRefGoogle Scholar
  28. 28.
    Padhani AR, Ollivier L (2001) The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 74:983–986PubMedGoogle Scholar
  29. 29.
    Ηotta N, Tgaya T, Maeno T, et al. (2003) Usefulness of contrast enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects of hepatocellular carcinoma. Hepatogastroenterology 50(54):1867–1871Google Scholar
  30. 30.
    Μichielsen PP, Francque SM, van Dongen JL (2005) Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 20(3):27–30CrossRefGoogle Scholar
  31. 31.
    Τakayasu K, Muramatsu Y, Maeda T, et al. (2001) Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system. Analysis of factors affecting recurrence and survival rates AJR 176:681–688Google Scholar
  32. 32.
    Song SY, Chung J, Han KW, et al. (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12(3):313–320PubMedCrossRefGoogle Scholar
  33. 33.
    Κim W, Clark TWI, Baum RA, et al. (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965–968CrossRefGoogle Scholar
  34. 34.
    Gerschwind FH, Kaushik S, Ramsey DE, et al. (2002) Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 13(11):1163–1166CrossRefGoogle Scholar
  35. 35.
    Patel S, Tuite CM, Mondschein JI, et al. (2006) Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol 17:1931–1934PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Katerina Malagari
    • 1
  • Katerina Chatzimichael
    • 1
  • Efthymia Alexopoulou
    • 1
  • Alexios Kelekis
    • 1
  • Brenda Hall
    • 4
  • Spyridon Dourakis
    • 2
  • Spyridon Delis
    • 3
  • Athanasios Gouliamos
    • 1
  • Dimitrios Kelekis
    • 5
  1. 1.Second Department of RadiologyUniversity of AthensAthensGreece
  2. 2.Second Clinic of Internal Medicine and HepatologyUniversity of Athens, and Department of Internal Medicine and Hepatology, Ippokration Hospital University of AthensAthensGreece
  3. 3.Department of SurgeryAgia Olga HospitalAthensGreece
  4. 4.Biocompatibles UK, Inc.SurreyUK
  5. 5.Research Centre of Radiology and ImagingUniversity of Athens, Evgenidion HospitalAthensGreece

Personalised recommendations